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ABSTRACT
An abstract of the thesis of Venkat Raghav Aachi for the Master of Science in Biology

presented March 13,2009.
Title:

Preliminary characterization of Mitochondrial ATP-sensitive potassium
channel (MitoKATP) activity in mouse heart mitochondria.
Myocardial ischemia, infarction, heart failure and arrhythmias are the

manifestations of coronary artery disease. Reduction of ischemic damage is a major
concern of cardiovascular biology research. As per recent studies, the mitochondrial
ATP-sensitive potassium channel (mitoKATP) opening is believed to playa key role in
the physiology of cardioprotection, protection against ischemia-reperfusion injury or
apoptosis. However, the structural information of mitoKATP is not precisely known.
Elucidating the structural integrity and functioning of the mitoKATP is therefore a
major goal of cardiovascular biology research. The known structure and function of
the cell ATP-sensitive potassium channel (cellKATP) is functional in interpreting the
structural and functional properties of mitoKATP .
The primary goal of my research was to characterize the activity of mitoKATP in
the isolated mitochondria from the control mouse heart. The mitoKATP activity, if
preliminarily characterized in the control strains through the light scattering technique,
then the structure of the channel could possibly be established and analyzed. by means

of the transgenic model and with the help of immunological techniques such as
western blotting and immunoflorescence.
With this experimental model it was possible to demonstrate that the mitoKATP
activity in control mouse heart mitochondria is activated by potassium channel
openers (KeOs) such as diazoxide and cromakalim and activators ofmitoKATP such as
PMA (phorbol12 myristate-l3-acetate), and inhibited by K ATP inhibitors such as
glibenc1amide and 5-hydroxydecanoate (5 HD).
It was evident that the mitoKATP activity in mouse heart mitochondria was

comparable to that exhibited by the rat heart mitochondria. The various selective and
non-selective activators and inhibitors of the channel elicited their activity at a similar
concentration used for the rat heart mitochondria. The results were reproducible in five
independent experiments for each combination, further reinforcing the significance of
existing channel activity in the mouse heart mitochondria.

2

PRELIMINARY CHARACTERIZATION OF MITOCHONDRIAL ATP
SENSITIVE POTASSIUM CHANNEL (MITOKATP) ACTIVITY IN MOUSE
HEART MITOCHONDRIA

by
VENKATRAGHAV AACHI

A thesis submitted in partial fulfillment of the
requirements for the degree of

MASTER OF SCIENCE
In

BIOLOGY

Portland State University

2009

DEDICATION
My work is dedicated to my parents, my brother and to all my friends

i

ACKNOWLEDGEMENTS
I would like to thank my advisor, Dr. Keith D. Garl~d, for being truly supportive of my
work throughout my tenure as a graduate student. I am thoroughly indebted to Dr.
Garlid for having introduced me to the world of clinical research, which I am sure, has
helped me grow as a clinician in specific, and a person in general.
I am extremely grateful to Dr. Stan Hillman and Dr. Debbie Duffield, for having
agreed to be on my committee, and helping me out with their careful evaluation of my
work and valuable comments.
I would like to thank Dr. Alex D. Costa, who taught me the intricacies of the various

experimental procedures, and guided me throughout the project with his technical
expertise.
My heartfelt thanks to Craig Semrad, for his tremendous support, technical advice and
cooperation.
I greatly appreciate the friendship and support of Casey, Abraham, Cynthia, Beau,
Ksenia, Nastia and other members of Dr. Garlid's lab.
I sincerely thank Dr. Michael Murphy and Dr. Suzanne Estess, for helping me out with
my graduation process.
Finally, I would want to thank my family and friends, without whom this journey
would not have been this worthwhile.

11

TABLE OF CONTENTS:
ACKNOWLEDGEMENTS

ii

LIST OF TABLES

VI

LIST OF FIGURES

vii

ABBREVIATIONS

IX

CHAPTER 1:
1.1

INTRODUCTION

1

Rationale for mouse as the study model

2

ATP-SENSITIVE POTASSIUM CHANNELS

4

2.1

Plasma Membrane / Sarcolemmal KATP Channels (CellKATP)

4

2.2

Physiological roles of cellKATP

5

2.3

Pharmacological directive of cellKATP

5

2.4

Structure of cellKATP

7

2.5

Mitochondrial KATP Channels (MitoKATP)

9

2.6

Regulation of matrix volume by MitoKATP

10

2.7

Oxidative phosphorylation

11

2.8

Myocardial Ischenlia and cardioprotection

11

CHAPTER 2:

111

2.9

MitoKATP as a receptor for KCOs and their inhibitors

12

2.10

Sulfonylurea receptor of mitoKATP

14

2.11

Kir subunit of mitoKATP

15

CHAPTER 3:

MATERIALS AND METHODS

16

3.1

Mitochondrial isolation

16

3.2

AssayMedium

17

3.3

Measurement of mitochondrial volume

18

3.4

Chemicals

20

CHAPTER 4:

KATP CHANNEL OPENERS AND BLOCKERS

21

4.1

Non-selective K ATP agonists

21

4.2

Selective nlitoKATP agonists

22

4.3

K ATP channel blockers

22

CHAPTER 5:
5.1

CHAPTER 6:

RESULTS

24

Mechanism of activation of mitoKATP by PMA

DISCUSSION

27

46

iv

REFERENCES

50

APPENDIX A: Mouse Heart Mitochondria isolation protocol

64

v

LIST OF TABLES

Table 1: Pharmacological agents currently under investigation ......... .

VI

29

LIST OF FIGURES:
Figure 1: Mitochondrial Potassium cycle. .. .. . .. . . .. .. . ... . . . . .. ... . . .... . . ...

30

Figure 2: Proposed interaction of regulatory ligands with mitoKATP.....

31

Figure 3: Intramitochondrial Signaling pathway. . . ... . . . . . . . .. ... . . . ... .. ...

32

Figure 4: Light scattering traces showing 5-HD inhibiting Diazoxide
in mouse heart mitochondria...... ...... .................. ........................

33

Figure 5: Light scattering traces showing Glibenclamide inhibiting
Diazoxide in mouse heart mitochondria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...

34

Figure 6: Light scattering traces showing 5-HD inhibiting Cromakalim
in mouse heart mitochondria ..................................................

35

Figure 7: Light scattering traces showing Glibenclamide inhibiting
Cromakalim in mouse heart mitochondria ................................. ..

36

Figure 8: Light scattering traces showing Glibenclamide inhibiting
PMA in mouse heart mitochondria ......................................... .

37

Figure 9: Light scattering traces showing 5-HD inhibiting PMA
in mouse heart mitochondria ............................................. ..

Vll

38

Figure 10: Summarized data for the percentage mitoKATP activity
exhibited by diazoxide and blockers 5 hydroxydecanoate (5 HD) and

glibenclamide.................................................................. .

39

Figure 11: Summarized data for the percentage mitoKATP activity
exhibited by cromakalim and blockers 5 hydroxydecanoate (5 HD) and
glibenclamide.................................................................

40

Figure 12: Summarized data for the percentage mitoKATpactivity
exhibited by PMA and blockers 5 hydroxydecanoate (5 HD) and

glibenclamide.................................................................. .

41

Figure 13: Light scattering traces showing mitoKATP activity in rat
heart mitochondria ............................................................ .

42

Figure 14: Comparing the % mitoKATP in rat vs. mouse heart...

43

Figure 15: Chemical structures ofKATPchannel activators ...........

44

Figure 16: Chemical structures ofKATPchannel blockers ............ .

45

viii

ABBREVIATIONS

ADP

Adenosine diphosphate

ATP

Adenosine triphosphate

APD

Action potential duration

ATPi

Intracellular ATP

BLM

bilayer lipid membrane

BSA

bovine serum albumin

CellKATP

plasma membrane KATP channel

CoA

coenzyme A

CRM

cromakalim

DAG

diacylglycerol

DEAE-cellulose

diethylaminoethyl-cellulose

DZX

diazoxide

DMSO

Dimethyl Sulfoxide

EDTA

ethylene diamine tetraacetic acid

EGTA

ethylene glycol tetraacetic acid

eNOS

endothelial nitric oxide synthase

FA

fatty acid

FADH2

reduced flavin adenine dinucleotide

FL-glyburide

BODIPY FL glibenclamide

GDP

guanosine diphosphate
IX

GTP

guanosine triphosphate

GLI

glibenclamide

5-HD

5-hydroxydecanoate

HEPES

4-(2-hydroxyethyl )-I-piperazineethanesulfonic acid

IP3

inositol 1, 3, 4 triphosphate

KCO

potassium channel opener

Kir

inward rectifying potassium channel

MitoKATP

mitochondrial KATP channel

MPT

mitochondrial permeability transition

NADH

a-nicotinamide-adenine dinucleotide

NBF

nucleotide binding fold

PAGE

polyacrylamide gel electrophoresis

PKC

protein kinase C

PMA

phorbol 12 myristate-13-acetate

PKG

protein kinase G

Pi

phosphate.

PLC

phospholipase C

P1P2

phosphatidyl inositol 4, 5 bisphosphate

SDS

sodium dodecyl sulfate

SlTR

sulfonylurea receptor

TEA

tetraethylammonium cation

TPP+

tetraphenylphosphonium ion
x

Walker A motif
Walker B motif

Xl

CHAPTERl
INTRODUCTION
Cardiovascular disease can manifest as acute myocardial infarction, myocardial
ischemia or arrhythmias [72, 75, 84]. Myocardial ischemia, as defined, is a reduction
in the blood supply to the heart muscle owing to the constriction or obstruction of the
coronary arteries. The lack of blood supply to the heart leads to a reduction in the
oxygen supply to the contractile heart muscle and eventual accumulation of toxic
metabolites, leading to a permanent damage to the heart tissue. The irreversible
necrosis of the heart tissue owing to the compromised blood supply manifests as
infarction. The infarcted heart tissue loses the power to regenerate and subsequently
ends up with a compromised ventricular function. [72, 75, 84]
Reducing the morbidity and improving the clinical outcome in patients with coronary
artery disease is a major concern of cardiovascular biology research. The
mitochondrial ATP-sensitive potassium channel (mitoKATP) is thought to have a
significant effect in the physiology of ischemic signaling pathway, protecting the
myocardium against the ischemia-reperfusion injury (considering the reduction in the
size of infarct when subjected to mitoKATP specific potassium channel openers during
ischemic preconditioning; an effect reversed in the presence of potassium channel
blockers) [46, 47]. It is therefore important to address questions regarding the
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structural and functional properties of mitoKATP to further delineate its role in health
and disease.

1.1

Rationale for mouse as the study model:

Mice are probably the only mammalian species that are subjected to routine genetic
manipulations. Also, the mouse genome is one of the most extensively studied
genomes. The structural subunit assembly ofmitoKATP is quite unclear. It is still a
matter of ambiguity what channel subunits constitute the mitoKATP .
Through my study I intended to preliminarily characterize the mitoKATP activity in
control mouse heart mitochondria. I believe that the mitoKATP activity if successfully
characterized in the control mouse strains would eventually facilitate in understanding
the structural constitution and assembly of the channel subunits through the study
model of transgenic mice and various immunological techniques. Also, I intended to
test the hypothesis that the mitoKATP activity exhibited in control mouse heart
mitochondria is similar and comparable to that exhibited in rat heart mitochondria.
The structure of mitoKATP could be understood in much detail by pursuing the model
of genetically modified mice (transgenic mice) with their cellKATP channel subunits
over-expressed or knocked-out. Performing light scattering experiments on the
isolated heart mitochondria from the transgenic mouse model, and by subjecting the
isolated mitochondria to various selective and non selective KeOs and blockers,
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would eventually facilitate in characterization of the mitoKATP activity in these study
models. The structural subunits constituting the mitoKATP could be analyzed through
various immunological techniques such as western blotting and immunoflorescence.
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CHAPTER 2
ATP- SENSITIVE POTASSIUM CHANNELS (KATP}

There are two types of KATP channels constituting the cardiac myocyte. These include,
the cellKATP channel / sarcolemmalKATP channel in the plasma membrane, and the
mitochondrial KATP (mitoKATP) in the inner membrane of the mitochondria [1, 44, 77,
82].
2.1

Plasma Membrane / Sarcolemmal KATP Channels (CellKATP)

The potassium channels form the prime component of plasma membrane of cells of
various tissues [1-6]. The potassium channels function in setting up a resting
membrane potential, regulating the electrical activity and ion transport across the
membrane. The ATP-sensitive potassium channels (KATP) were first identified in the
plasma membrane of cardiac myocyte by Noma through his experiments using single
channel patch clamp techniques [1]. CellKATpare expressed in diverse tissues of the
body that include pancreatic ~ cells, skeletal muscle, smooth muscle and neurons of
the brain parenchyma, in addition to the cardiac cells. [2,3,4,5,6]
The cell ATP-sensitive potassium channels are involved in a variety of regulatory
functions that include shortening of the action potential duration in cardiac myofibrils,
loss of K+ ions during functional inhibition in heart, regulation of the skeletal muscle
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excitation, pancreatic ~-cell release of insulin, relaxation of smooth muscle and the
release of various neurotransmitters from the neurons of brain parenchyma [7, 8, 9].

2.2

Physiological roles of CellKATP

The opening of the cellKATP leads to hyperpolarization of the cell plasma membrane.
Hyperpolarization of the pancreatic

~-cells

inhibits glucose-stimulated insulin

secretion by preventing the increase in intracellular Ca+2. Depolarizing the plasma
membrane of the pancreatic ~-cells leads to opening of voltage gated Ca+2 channels,
elevation of intracellular Ca+2 and eventual exocytosis of insulin granules [10]. In the
myocardium, excess efflux of K+ leads to a reduced influx of Ca+2 by decreasing the
action potential duration. This reduced intracellular Ca+2 results in a reduction in the
contractility of the heart and possible rhythm disturbances during ischemia [11, 12].
The cellKATP opening in the arteriolar smooth muscles results in a reduction in blood
pressure, primarily mediated through a fall in the arteriolar resistance [13].

2.3

Pharmacological directive of cellKATP

Intracellular ATP (ATPi) and ADP primarily regulate the activity of the cellKATP [4].
ATPi is functional in closing the channel and maintains the channel activity in the
presence of Mg+2 [14-17]. Under normal physiological concentrations of A TPi, the
probability of cellKATP to be in an open state is minimal. The ATP i is viewed to be
bound to the cellKATP, for the channel to remain in the closed state. Hydrolysis of ATP
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in the presence of Mg+2 emphasizes the pivotal role of protein phosphorylation in
maintaining the channel activity [7].
The A TP inhibition of KATP channels is reversed by a class of drugs called potassium
channel openers (KCOs) that include cromakalim, diazoxide, minoxidil, pinacidil and
nicorandil. The properties ofKATP channels vary among tissues. For example pinacidil
activates cardiac cellKATP but diazoxide does not; the pancreatic

~-cellKATP activity

is

weak in the presence of pinacidil, but shows significant activity with diazoxide. Both
diazoxide and pinacidil effectively activate smooth muscle cellKATP resulting in
vasodilatation [7, 21, 22]. The differential activities exhibited by cellKATP lead to the
assertion that there are receptor subtypes among cellKATP. [21,22]
Glyburide and glibenclamide, which belong to the sulfonylurea class of anti-diabetic
drugs, have also been found to block the activity of KATP . Inhibition of KATP channel in
the pancreatic

~-cells

leads to a series of events that eventually result in the release of

insulin, and hence sometimes referred to as insulin secretagogues considering their
pro-insulin action [3, 24, 25]. Their action on the cardiac and smooth muscle cells
requires higher concentrations than in the pancreatic

~-cells

[23]. Glyburide and

glibenclamide are not really indicated in patients susceptible to ischemia, as they have
been found to reverse the cardioprotective effects of the KCOs and result in rhythm
disturbances [13, 19]. The inhibition ofKATP by ATP is independent of
phosphorylation and the sensitivity of KATP channel to A TP is reduced in the presence
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of ADP [70]. Glyburide and Glibenclamide are classified as non-specific K ATP channel
antagonists, considering their inhibitory action on the cellKATP and the mitoKATP .
(Table 1)

2.4

Structure of cellKATP

The complex of two different protein subunits namely, the inward-rectifying
potassium channels (Kir) and the sulfonylurea receptor (SUR), form the cellKATP [28].
The Kir can exist either as Kir6.1 or Kir6.2 [18, 27] and the SUR can exist as SURl,
SUR2A or SUR2B [29-31]. The regulatory SUR belongs to the ATP-binding cassette
transporter family (ABC) [32,33, 72, 77]. The Kir subunit acts as a potassium
conducting pore. The SUR subunit primarily regulates cellKATP activity [29, 30, 72,
77].
The complementarity-determining DNA (cDNA) that encoded for Kir6.1 was initially
isolated from the pancreatic islet cDNA library of the rat [25]. The composition of rat
Kir6.1 primarily included two transmembrane domains with a 424-amino acid residue
protein (Mr = 47,960). The Kir6.2 fragment was isolated by means of the Kir6.1 as the
probe for screening the human genomic library [34]. The Kir6.1 was almost 70%
identical to the Kir6.2 as revealed by the amino acid sequences [34,35]. The truncated
form of Kir6.2 (with the last 26 or 36 amino acids deleted), when expressed in the
absence of SUR, is found to be insensate to sulfonylureas, diazoxide, cromakalim and
Mg-ADP [18, 36].
7

SURI was recognized by means of radiolabeled analogs of glyburide. They were
isolated in pancreatic

~-cells

as a 140 kD protein on SDS-Polyacrylamide gel

electrophoresis [26, 37]. Molecular cloning of SURI exposed that it encoded proteins
of 1582 amino acids with 13 transmembrane domains and two nucleotide-binding
folds (NBF) [31].
The cellKATP from the pancreatic

~-cells

co-express SURI and Kir6.2 [34]. Mutations

in NBF 1 and NBF2 are viewed as functional in the pathophysiology of familial
hyperinsulinemic hypoglycemia of infancy [38, 39]. Walker A (WA) motifs ofNBFl
and NBF2 are thought to be prospective sites of Mg-ADP activation of cellKATP [40].
The activation ofKATP channels by diazoxide required the W A motifs ofNBFl and not
NBF2 [40].
The diverse isoforms of SUR, when co-expressed in various combinations with Kir
subunits, demonstrates different sensitivities [29, 36]. For example the SUR2A /
Kir6.2 complex regulates the activity of cellKATP in cardiac and skeletal muscle. This
combination is more sensitive to pinacidil than to diazoxide [29]. The SUR2B / Kir6.2
complex regulates the cellKATP activity of smooth muscle and is sensitive to both
pinacidil and diazoxide [30]. Thus, the sensitivity of cellKATP to sulfonylureas,
diazoxide and cromakalim requires the presence of SUR and the activation of the
cellKATP by Mg-ADP also requires the presence of SUR [36].
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The verity that SUR1 contains two NBF whereas Kir6.2 has none, favors the
assumption that inhibition of the channel by ATP requires binding of ATP to SUR
[29,31]. The sensitivity of truncated Kir6.2 to ATP is enhanced by SUR1 as is evident
from the shifting ofKi from approximately 100 IlM to 10 IlM [36].

As per recent studies it has been demonstrated that the Kir and the SUR subunits are
associated with 1: 1 stoichiometry [41, 42, 43, 77]. The data also indicate that the
channel pore of cellKATP is lined by four Kir subunits and four SUR regulatory
subunits surrounding it, eventually functioning as a hetero-octameric structure [72,
77].

The mitoKATP is thought to be qualitatively similar to the cellKATP, comprising the
potassium conducting pore forming Kir subunit and the regulatory SUR subunit
surrounding it. [51, 65, 90] [Fig 2]

2.5

Mitochondrial KATP Channels (MitoKATP)

Inoue et aI., in 1991, through their patch clamp studies on fused giant mitoplasts
(mitochondria stripped of their outer membrane) from rat liver mitochondria, first
reported the existence of A TP sensitive K+ channels in the hmer membrane of the
mitochondria [44]. The principal properties of mitoKATP include its improved
sensitivity to K+ ions in comparison to Na+ and TEA+, high affinity inhibition with
ATP and long chain acyl-CoA esters [44, 45], KCOs activation of the ATP inhibited
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channels [46,47], and inhibition of the channel by glyburide, glibenclamide and 5
hydroxydecanoate (5HD) [45,47,48]. All these physiological and pharmacological
actions exhibited by mitoKATP are thus similar to cellKATP, although with a much lower
conductance (10 pS in 100 mmol/L cytosolic K+ and 33 mmollL matrix Kl [44].

2.6

Regulation of matrix volume by MitoKATP

The opening ofmitoKATP has been proposed to cause an increase in steady state
matrix volume, respiratory stimulation (uncoupling), and alkalization of the
mitochondrial matrix [72, 77]. The electrophoretic K+ uptake across the inner
mitochondrial membrane is mediated through the process of diffusion and mitoKATP,
as demonstrated by the mitochondrial potassium cycle [Fig. 1]. This influx of K+ under
steady state is balanced by the electrophoretic H+ efflux through the electron transport
chain. The mitochondrial matrix volume is determined by the net flux of K+ across the
inner membrane along with the flux of anions like phosphate and osmotically
regulated water [49, 70, 72, 77]. Opening of the mitoKATpleads to the influx ofK+
across the inner mitochondrial membrane and an eventual swelling of the
mitochondrial matrix, with a minimal effect on the matrix K+ concentration. This net
influx of K+ activates the electroneutral K+ / H+ antiporter that provide a compensatory
K+ efflux so as to maintain a new steady state for a higher matrix volume [49-51]. The
proton motive force derived from the electron transport chain provides the required
energy to cause the movement of ions across the membrane. [Fig 1]
10

2.7

Oxidative phosphorylation

The electrons carried by NADH and FADH2 get combined with molecular oxygen
through the electron transport chain. Peter Mitchell proposed the chemiosmotic
hypothesis in order to understand the synthesis of ATP through the coupling of
substrate oxidation [52]. The energy required to pump the H+ across the inner
mitochondrial membrane from the matrix to the intermembrane space, is derived from
the movement of electrons from the hydrogens on NADH and F ADH2, as they pass
along the respiratory chain. The synthesis of A TP by ATP synthase is mediated
through the electrochemical gradient created by the movement of electrons. Oxidative
phosphorylation is eventually concluded by the catalytic translation of ADP and Pi to
ATP [52].

2.8

Myocardial Ischemia and cardioprotection

Myocardial ischemia is a phenomenon of reduced blood supply to heart muscle due to
the constriction or obstruction of the coronary arteries, resulting in an imbalance
between the supply and demand for coronary arterial blood supply. As a result of this
imbalance there is an accumulation of potentially toxic metabolites such as protons,
carbon dioxide and lactic acid. Also there is a dearth of oxygen, substrates and energy
in the tissues. The energy for myocardial contractility is derived from mitochondrial
oxidative phosphorylation which subsequently influences the myosin ATPase activity.
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The functions of the mitochondria are thus of prime importance in the molecular
events that lead to compromised myocardial function. [75]
Subjecting the myocardiunl to repetitive alternating periods of ischemia followed by
reperfusion, eventually followed by a prolonged ischemia-reperfusion, reflects
ischemic-preconditioning (IPC) [75, 82]. Following ischemia, there is ATP depletion
and subsequent reperfusion washes out the ischemic metabolites [53]. KCOs when
used during ischemic preconditioning are cardioprotective, as evidenced by the size of
the heart muscle infarct [20, 54, 75, 82]. This protective effect of KCOs is blocked by
glyburide, glibenclamide and 5-hydroxydecanoate (5HD) [19, 20, 55, 75, 82].
KCOs through their action on the cardiac cellKATP are considered to cause a
shortening of the action potential duration (APD) and hence protect the ischemic
myocardium [56]. However, a lack of correlation between monophasic APD and
cardioprotection by KCOs has resulted in contradicting this hypothesis, thus
suggesting that the site of action of KCOs in cardiac muscle cells is discrete from
cellKATP [57, 58]. This discrete site of action of cardioprotective effects of various
KCOs is believed to be the mitoKATP . [65, 72]

2.9

MitoKATP as a receptor for KCOs and their inhibitors

MitoKATP, a central intracellular pharmacological receptor is inhibited by A TP, and
this inhibited mitoKATP is potentially activated by KCOs [46,47,48, 59, 60].
Cromakalim and Diazoxide, the prime activators of mitoKATP , act in the low
12

micromolar range [46]. The distinct nature of the two cardiac KATP channels i.e.,
cellKATP and mitoKATP could probably be established through diazoxide which is more
potent in activating the cardiac mitoKATP (K Y2, 0.4 JlmoIlL), roughly 2000 times more
potent than for activating cardiac cellKATP (855 JlmollL) [46]. Glyburide,
glibenclamide and 5HD, when studied in intact mitochondria, have been shown to act
as inhibitors ofmitoKATP in the presence of ATP, Mg+2and a pharmacological opener
such as diazoxide, cromakalim, or a physiological opener such as GTP [48].
Cardiac mitoKATP, but not cardiac cellKATP, is susceptible to the action of 5 HD and
diazoxide and the cardioprotective effects of diazoxide are blocked by 5 HD [47]. It
was eventually hypothesized by Garlid et al. that the phenomena of cardioprotection
by KCOs in cardiac muscle cells was mediated through mitoKATP [47]. Liu et al.
through their experiments on intact ventricular myocytes, showed that diazoxide was
mitoKATP specific and not cellKATP specific [59]. Protein kinase C (PKC) mediated
activation of mitoKATP is a key element in the phenomenon of ischemic
preconditioning (IPC), as emphasized by Sato et al. [60-64].
It was recommended by Inoue et al. [44] and Halestrap [83] that the regulatory sites of
the mitoKATP nucleotides faced the mitochondrial matrix. Subsequently Garlid et al.
through their studies on mitoKATP reconstituted into proteoliposomes and lipid bilayer
membranes (BLM), concluded that the mitoKATP was unidirectional with respect to
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nucleotide access and that the nucleotide binding sites of mitoKATP faced the cytosol
[70].

2.10

Sulfonylurea receptor of mitoKATP:

Garlid et al. viewed that the mitoKATP comprised an inward-rectifying K+ channel
(mitoKir) and a regulatory sulfonylurea receptor (mitoSUR), as was thought of in
cellKATP [51, 65, 901 Paucek et al. through their studies using BODIPY-FL glyburide
to photolabel inner mitochondrial membrane vesicles identified a protein that was
precise and migrated at 63kD on SDS-Polyacrylamide gel electrophoresis [66, 67].
The fraction containing the 63kD protein (identified on partial purification on DEAE
cellulose medium), when reconstituted in lipid vesicles, exhibited mitoKATP properties.
It was henceforth hypothesized to be the regulatory sulfonylurea receptor of mitoKATP

[67].
Szewczyk et al. through photoaffinity labeling of sub-mitochondrial particles with
[I

125

]-glibenclamide, recognized a 28kD inner mitochondrial membrane protein. This

identified membrane protein demonstrated the activity of low-affinity sulfonylurea
binding protein with an apparent Ko of 360 nM and BMAX of 48 pmol per mg of inner
membrane protein [68].
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2.11

Kir subunit of mitoKATP•

Mironova et aI., on reconstituting an ATP-dependent K+ channel in the lipid bilayer
using rat liver mitochondria, identified an activity with 55kD protein, that was
inhibited with low affinity by ATP (K1I2 approximately 550 J.1M). They eventually
suggested it to be the Kir subunit [69, 90]. MitoKATP activity was witnessed in
liposomes that were reconstituted with partially purified fraction using rat liver and
beef heart mitochondria by Paucek et al. [45]. The identified protein contained a major
protein band at 54kD [45], with a saturating conductance of 30 pS (1 mollL KCI).
Further studies are awaited that can help identify and sequence the alleged Kir subunit
of mitoKATP .
The mitoKATP activity characterized in the control mouse model would eventually
facilitate in understanding further the subunit assembly of mitoKATP through the
medium of genetically modified/transgenic mice and various immunological
techniques.
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CHAPTER 3

MATERIALS AND METHODS
3.1

Mitochondrial isolation:

Inbred strain mice of type C57BL/6J from the Jackson lab were used for all the
experiments. Three mice were used for each experiment in order to isolate significant
amount of mitochondrial protein. The mice were anesthetized with CO 2 for one
minute, incised through the abdomen, sternotomy performed and the hearts were
excised. It was our observation that the time interval between the hearts excision and
completion of homogenization influenced the channel activity (brief period of 2
minutes); the lesser the time interval, the better the channel activity. The hearts were
washed in ice cold Buffer A (250mM sucrose, 10mM HEPES, 5mM EGTA and pH
7.2). The hearts were pounded with protease Imglml (type XXIV Sigma). The
suspension was diluted up to two to threefold with buffer A supplemented with 0.5%
bovine serum albumin (BSA). The suspension was then poured into a motorized
Teflon pestle so as to get it homogenized. The homogenized suspension was then
centrifuged in a Sorvall centrifuge for 3 minutes at 1500 g. The supernatant obtained
was then centrifuged at 9000 g for 5 minutes. The consequential pellet was
resuspended in Buffer A without BSA and centrifuged for 3 minutes at 2300 g. The
ensuing supernatant was centrifuged for 5 minutes at 9000 g. The resulting final pellet
was resuspended in Buffer A without BSA so as to have the final concentration as 35
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40 mg/ml protein and was placed on ice. This technique of mitochondrial isolation is
in agreement with that described by Jaburek et al. [48, 72, 77, 84] (Appendix A). The
mitochondrial protein concentration was projected by means of the Biuret reaction
[71]. Mitochondrial protein was assayed within two hours of isolation. The isolated
mitochondria were placed on ice and were continuously stirred with the help of a
magnetic stirrer to ensure free oxygen access during the experiments. This practice is
in agreement with the American Physiological Society's "Guiding principles in the
Care and Use of Animals", and was permitted by the Institutional Animal Care and
Use Committee (IACUC) at Portland State University, Oregon. [72, 77, 84]

3.2

Assay Medium:

The mitochondria were suspended in an assay medium consisting of potassium
chloride (KCI) (120mM); EGTA (O.lmM) (chelator of calcium ions); succinate
(lOmM) (provides electrons to electron transport system); phosphoric acid (5mM); 0.5
mM MgCh and pH 7.2. The osmolality range of the assay medium, as measured by
the osmometer, was between 275-280 mosmollkg H 20. All the runs were
supplemented with 5 flM Rotenone and 0.67 flM Oligomycin. The experiments were
performed at 30.5 °c [72, 77,84].
Rotenone is functional in inhibiting the reverse electron transfer from complex II to
complex I of the electron transport chain. Oligomycin inhibits FoFt-ATP synthase of
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the electron transport chain. The synthesis of ATP is henceforth interrupted and the
membrane potential is subsequently decreased. [72, 77, 84]
The volume of the assay medium used for experiments involving rat heart
mitochondria was 3 ml in my lab. I tried to reduce the volume and work with the 1.5
ml assay medium in order to perfonn significant number of light scattering runs to
validate the mitoKATP activity.

3.3

Measurement of mitochondrial volume:

K+ uptake is assayed following the mitochondrial matrix swelling. The light scattering
technique is functional in measuring the changes in mitochondrial volume that escort
the net salt transport into the mitochondria. The light scattering technique is based on
the principle that the reciprocal absorbance (A-I) at 520 nm and 0.1 mg/mlofthe
mitochondrial suspension at 30.5 °c, is linearly related to matrix volume, as described
by Beavis et al. [71, 72]. ~ is a dimensionless factor that nonnalizes A-I (inverse
absorbance) for mitochondrial protein concentration, P (mg/ml)

a is a machine constant (0.25 for our apparatus) and P s equals 1 mg/ml. [72, 77, 84]
An increase in matrix volume, owing to the osmotic swelling of mitochondria (due to
uptake of salts and water), is accompanied by a decrease in light intensity. The light
scattering technique measures this change in matrix volume of the mitochondria. The
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light scattering technique is primarily functional in investigating the mitoKATP activity
in intact isolated mitochondria. The light scattering technique is beneficial in
comparison to the reconstitution studies, considering that the mitochondrial ion
channels and the bioenergetic apparatus are intact and also the various regulatory
agents could possibly be applied directly to the mitochondria. Limitations include the
unphysiological ion gradient's usage, substrate or nucleotide concentrations, and a
possible influence of neighboring organelle membranes [48]. The data measured by a
Brinkmann PC 700 light probe is converted to digital information (A- 1) using a "Lab
view" program designed exclusively for use in our laboratory. [72, 84]
Diazoxide, and other hydrophobic compounds soluble in dimethyl sulfoxide (DMSO),
are always added 2-3 seconds after the mitochondrial suspension to guarantee equal
distribution. Also, diazoxide is not effective in the absence of ATP, since it cannot
activate a channel that is previously in its open state. Similarly, 5 hydroxydecanoate (5
HD), a specific mitoKATP antagonist is ineffective in the absence of ATP and the KCO
diazoxide. This is because 5 HD prevents the diazoxide mediated mitoKATP activation,
but by itself does not inhibit the channel activity. The same observations hold good for
cromakalim, PMA and glibenclamide as well. Light scattering traces were initiated on
adding the mitochondrial suspension with the first 5-7 seconds omitted for precision.
The channel activity was followed over a period of 180 seconds. [72, 77, 84]

19

The final concentration of the stock mitochondria added to the assay medium was 0.1
mg protein/ml. The volume of the assay medium was 1.5 ml for each run. Data
analysis followed each individual experiment. Rate of swelling was determined by the
slope of the traces on addition of the various KCOs, activators of mitoKATP and their
blockers. The analysis program used was "ORIGIN", a data-analysis program by
Microcal (Northampton, MA, USA). [72, 84]
Statistical analysis: Data are presented as mean +/- SD. Data were analyzed using
unpaired Student's t-test of the means using Microcal Origin software (Northampton,
MA). A value of P < 0.05 is considered statistically significant.
3.4

Chemicals

All the chemicals used for the experiments were from Sigma Chemical Co. (St. Louis,
MO, USA). Mice were ordered from the Jackson laboratory (Maine, USA).
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CHAPTER 4
KATP

CHANNEL OPENERS AND BLOCKERS:

One of the most credible means to establish and identify the functions of cardiac
sarcolemmal and mitochondrial KATP channels is through the medium of KATP channel
openers and blockers. The pharmacological agents could probably be classified as
selective and non-selective based on their putative sites of action in heart, the former
acting exclusively on the mitoKATP and the latter acting either on SarCKATP / mitoKATP
as shown in Table 1 and represented structurally in figures 15 and 16.

4.1

Non-selective KATP agonists:

Cromakalim, synthesized in 1980 represents the archetype of the benzopyrans class of
drugs. Used as a cardioprotective drug in experimental routines, it lacks specificity in
its site of action (mitoKATP vs cellKATP ). It functions in shortening the action potential
duration (APD) and causes vasodilatation [80, 82].
Nicorandil, belongs to the pyridyl nitrate class of drugs and causes significant
vasodilatation due to its NO (nitric oxide) donor properties. It has a non-specific site
of action in the cardiac myocyte [80, 82].

P 1075 is a widely studied potent cyanoguanidine. It lacks selectivity versus the
mitoKATP as was shown in ischemia-reperfusion studies on rat and rabbit cardiac
myocytes [82].
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4.2

Selective mitoKATP agonists:

Diazoxide, a benzothiazidine class of drug is a selective mitoKATP agonist under
normal conditions. It also causes activation of smooth muscle KATP and endothelial
KATP isoforms. Diazoxide is probably the only K ATP opener that binds equivocally to
SUR 1 and SUR 2B subunits. It is routinely used in low doses to establish the
importance of mitoKATP in preconditioning. A long term use of diazoxide is related to
the development of hyperglycemic state owing to its role in insulin inhibition [46, 82].
BMS-191095 «3R)-trans- 4-« 4-chlorophenyl)-N-( 1H-imidazol-2-ylmethyl)dimethyl
2H-l-benzopyran-6-carbonitril monohydrochloride) belongs to the benzopyrans class
of drugs with a higher cardiac selectivity and anti-ischemic potency. It was shown to
improve the post- ischemic cardiac function and a reduction in the LDH (lactate
dehydrogenase) release. Grover et a!. through their studies using reconstituted
mitoKATP observed that BMS 191095 activated the mitoKATP and the activation was
inhibited by both 5 HD and glibenclamide [79, 82].

4.3

KATP channel blockers:

5 HD (5 hydroxydecanoate), regarded as a specific inhibitor ofmitoKATP, is used in
most studies to assess the activity of the mitoKATP channel. It has been observed that
the diazoxide activated mitoKATP influx of K+ ions is reversed in the presence of 5 HD
in isolated rat heart mitochondria [48].
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Glibenclamide, an anti-diabetic drug belonging to the sulfonylurea class, is
implemental in blocking the activity of the KATP channel. It shows marked variability
in its actions with different affinity grades, exhibiting SUR1 blocking properties
involving pancreatic KATP and the SUR2A12B subunits expressed on the cardiac and
the vascular cells [80, 82].
HMR 1098 belongs to the sulfonylthiourea class and is considered as a selective
cellKATP blocker. It is generally used along with a non-specific K ATP blocker to
examine the physiology of IPC [81].
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CHAPTER 5
RESULTS:
The effects of ATP, KCOs (diazoxide, cromakalim), mitoKATpactivators (such as
PMA) and inhibitors (5 HD and glibenclamide) on mitochondrial matrix swelling
are potassium-specific.
The mitochondrial potassium cycle is an important constituent in maintaining the
mitochondrial volume homeostasis [Fig 1]. The swelling of the mitochondrial matrix
is witnessed as an increase in light scattering and is proportional to the net salt influx
[72, 77, 84]. The light scattering technique is functional in investigating the mitoKATP
activity in intact isolated mitochondria. The typical light scattering traces from control
mouse heart mitochondria in a respiring K+ rich medium are shown in figures 4 - 9.
Figure 4 demonstrates light scattering traces from mouse heart mitochondria respiring
in succinate supplemented K+ medium at 30.5 °C. The light scattering parameter ~, an
index of matrix volume, is plotted against time. In the absence of ATP (open/control),
the mitochondrial matrix attained a higher steady state volume. On addition of 200 JlM
ATP there is an apparent lower rate of swelling and ultimately a lower steady state
volume (ATP). The ATP inhibition of the channel was reversed by 30 JlM diazoxide
(ATP + DZX), and the opening effect of diazoxide was blocked by 300 JlM 5 HD
(ATP + DZX + 5 HD). [Fig. 4]
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Figure 5 demonstrates light scattering traces from mouse heart mitochondria respiring
in the same succinate supplemented K+ medium at 30.5 °C. In the absence of ATP, the
mitochondrial matrix scaled to a higher steady state volume. Addition of 200 )lM ATP
lowered the rate of swelling. The inhibition of the channel by ATP was reversed by 30
)lM diazoxide, and the activator effect of diazoxide was inhibited by 10 )lM
glibenclamide. [Fig. 5]
Figures 6 and 7 demonstrate light scattering traces initiated from mouse heart
mitochondria respiring in the same K+ medium supplemented with succinate. It was
evident that the mitochondria had swollen to a new steady state volume in the absence
of ATP (open) and the addition of 200 )lM ATP lowered the swelling. The channel
was re-activated by cromakalim (50 )lM) and this activator effect was inhibited by
both 5 HD (300 )lM) and glibenc1amide (10 )lM). [Fig. 6 & 7]
Figures 8 and 9 illustrate the light scattering traces demonstrated by isolated mouse
heart mitochondria respiring on succinate supplemented K+ medium. The
mitochondria, owing to the matrix swelling, attained a new steady state volume in the
absence of ATP (open! control trace), an effect inhibited ill the presence of 200 )lM
ATP. On addition of a PKC€ activator PMA (0.2 )lM), the mitoKATP got reactivated
and almost superimposed on the open trace. But this activated mitoKATP was inhibited
by both 5 HD (300 )lM) and glibenc1amide (10 )lM). [Fig. 8 & 9]
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Figures 10, 11 and 12 graphically illustrate the summary of the percentage mitoKATP
activity exhibited by isolated mouse heart mitochondria in the presence of activators
diazoxide, cromakalim, PMA, and inhibitors 5 HD, glibenclamide. The data establish
the capacity of ATP to inhibit the channel, the openable effects of various KCOs and
the inhibitory actions of K+ channel blockers. P value was less than 0.05 and hence
statistically significant. The data also validates the monitoring capacity of the assay
medium. The results summarized represent five independent experiments for each
combination. Data are presented as mean +/- SD. Data were analyzed using unpaired
Student's t-test of the means using Microcal Origin software. P < 0.05 is considered
statistically significant.
Figure 13 represents typical light scattering traces from rat heart mitochondria
respiring in succinate supplemented K+ medium (120mM) at 30.5 °c. It can be noted
that the mitochondrial matrix had swollen to a higher steady state in the absence of
ATP (open/control). When 200 J-lM ATP was added it resulted in a lower steady state
volume. ATP inhibition was overcome by 30 J-lM diazoxide and the diazoxide
activated channel was inhibited by 300 J-lM 5 HD [Fig. 13]. The light scattering traces
look similar to those in the mouse heart mitochondria. The results obtained with the
combination of diazoxide and 5 HD were reproducible by combining diazoxide +
glibenc1amide (10 J-lM), cromakalim (50 J-lM) + 5 HD or cromakalim + glibenclamide,
and also PMA (0.2 J-lM) + 5 HD or PMA + glibenc1amide. (data not shown)
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Figure 14 demonstrates bar graphs representing the comparison between percentage
mitoKATP activity exhibited by rat and mouse heart mitochondria under the same
experimental conditions. Rates in the absence of ATP were set as 100% and in the
presence of ATP as 0%. The effects of various KCOs and blockers are assessed in
relation to the set controls. It can be seen that the percentage mitoKATP activity
exhibited by mouse heart mitochondria is comparable to that exhibited by rat heart
mitochondria when subjected to various potassium channel openers and their blockers.
Data are presented as mean +/- SO. Data were analyzed using unpaired Student's t-test
of the means using Microcal Origin software.

5.1

Mechanism of activation of mitoKATP by PMA:

PMA is a protein kinase C epsilon (PKCe) activator which eventually activates the
mitoKATP . The activation of PKCe phosphorylates the mitoKATP and ultimately opens
it. PKCe has been shown to be bound to the inner membrane of the mitochondria and
associated in a functional complex with mitoKATP. This was demonstrated using the
techniques of detergent extraction and chromatographic isolation of mitochondrial
membrane proteins. The PKCe activated mitoKATP results in an influx of potassium,
an effect negated in the presence of phosphatases. The K+ influx causes the matrix
alkalinization, retarding the reduction ofQ to QH2 at Complex 1 of the electron
transport chain and eventually resulting in the H20 2 production by reducing the
molecular oxygen. MitoKATP activated K+ influx and eventual ROS (reactive oxygen
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species) production is mediated through the KCOs and also mitoKATP associated
PKCB activation [75, 78]. [Fig 3]
When used in the 0.2 JlM concentration, the PKCB mediated activation of mitoKATP by
PMA was inhibited by both 5HD and glibenc1amide. [Fig 8,9, 12]
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Table 1:
Pharmacological agents currently under investigation to validate the KATP
channel activity:

Pharmacological agent

Putative site of action in Agonist!Antagonist
heart

Cromakalim

CellKATplMitoKATP

Agonist

Nicorandil

CellKATPlMitoKATP

Agonist

Diazoxide

MitoKATP

P-I075

CellKATP/MitoKATP

Agonist

BMS191095

MitoKATP

Agonist

5-hydroxydecanoate

MitoKATP

Antagonist

I

Agonist

Glybriride/Glibenclamide MitoKATP ICellKATP

Antagonist

HMR-I098

CellKATP

Antagonist

TPP

MitoKATP ICellKATP

Antagonist

Table 1 demonstrates the various pharmacological agents currently under investigation
worldwide to assess the ATP-sensitive potassium channel (KATP) activity along with
their putative sites of action in heart and their mode of action (agonist vs. antagonist).
Cromakalim, Nicorandil and P-I075 are considered as non-selective agonists ofKATP
since they are believed to act on the cellKATP and the mitoKATP . Diazoxide and
BMS191095 are considered tobe mitoKATP specific agonists. 5-hydroxydecanoate
(5H;D) is a mitoKATP specific antagonist and HMR-l 098 is a cellKATP specific
antagonist. Glyburide, Glibenclamide and TPP are non-selective KATP channel
antagonists.
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Mitochondrial Potassium Cycle
Intermembrane Space

H+

H+

H+

Electron Transport
System

K+
K+

K+

K+

H+

lea~

H+
K+

Mitochondrial Matrix

Fig 1: Mitochondrial Potassium cycle. The proton motive force that is generated by
the electron transport system creates a membrane potential that drives K+ influx via
diffusion (K+ leak) and mitoKATP (located on the inner membrane). The electroneutral
Pi/OH exchanger drives phosphate inside so that the net K+ influx is accompanied by
anions and osmotically obligated water. The electroneutral K+/ H+ antiporter regulated
on the matrix side by volume changes, Mg+2 and H+, provides an efflux of excess K+
accompanied by Pi and water, thereby preventing excessive matrix swelling. [49, 50,
51, 77]
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Proposed interaction of regulatory ligands with mitoKATP

Mitochondrial
matrix

IMS
Cromakalim
P1075
BMS191095?
Nicorandil?

ATP+ Mg+2
Glibenclamide
5-HD

Diazoxide
GTP

UDB
DEB

Fig 2: A proposed illustration of the mitoKATP channel subunits with the possible
interaction sites of the regulatory ligands (illustration modified from reference
[90]). MitoKATP is thought to be represented by four 55-kDa Kir subunits and four 63
kDa SUR subunits, functioning as a hetero-octamer. MitoKir is viewed as a
conduction pore of the channel and is surrounded by the regulatory SUR subunits that
contain one or more nucleotide binding folds (NBF). The Kir subunits regulate the
movement ofK+ across the membrane. The Kir subunits are thought to mediate the
inhibitory effects of ATP (in the absence of Mg+2) and TPP+, and activation effects of
UDP and DEB. The SUR subunits, belonging to the ABC family, demonstrate the
sites of possible inhibition by ATP + Mg+2, Glibenclamide and 5-HD. The activation
of the channel by diazoxide, GTP, cromakalim, PI075 and possibly BMS191095 and
nicorandil, is thought to be mediated through the SUR subunits. [90]
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Intramitochondrial signalling pathway" PMA mode of action

Cardioprotection

KCOs

t
MPT

------------

1M

IMS

-------------------------·OM

Fig 3: Intramitochondrial signalling pathway triggered by cGMP activated
mitoKATP (illustration modified from reference [78]).PKG delivers the signals to
the mitochondria that arise from the Gi- coupled receptors. The signal is transmitted to
PKC€ 1 located on the inner mitochondrial membrane (IM) from PKG phosphorylation
of an unknown mitochondrial outer membrane (OM) protein. Activated PKC€ l causes
phosphorylation and opening of the mitoKATP . MitoKATP opening via PKC€ 1 activation
by PMA or by KATP channel openers such as diazoxide or cromakalim results in K+
influx, increase in matrix pH and increased H2 0 2 (reactive oxygen species)
production. The H 20 2 produced inturn activates PKC€ 1 and PKC€2. The activated
PKC€2 inhibits the mitochondrial permeability transition (MPT) which eventually
decreases cell necrosis, infarct size and inhibits apoptosis. [75, 78, 82]

Abbreviations used: cGMP, cyclic Guanosine monophosphate; PKG, protein kinase
G; PM A, PhorboI12-myristate-13-acetate; OM, outer membrane; 1M, inner
membrane; IMS, inter membranous space; PKC ,€ protein kinase C epsilon; H2 0 2 ,
hydrogen peroxide; MPT, mitochondrial permeability transition; mkATP,
mitochondrial KATP ; "+" sign indicates activation; "-" sign indicates inhibition
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Light scattering traces illustrating mitoKATP activity in mouse heart
mitochondria:

5HD inhibits diazoxide activated nitoKATP
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Fig 4: 5-hydroxydecanoate (5 HD) inhibits the pharmacological opening of
mitoKATP by diazoxide. Light scattering traces from mouse heart mitochondria
respiring on succinate in IC medium (120 mM) at 30.5 °C. The light scattering
parameter p, an index of matrix volume, is plotted against time.
Trace a: K+ influx in the absence of ATP (open/control)
Trace b: K+ influx in the presence of 0.2 mM ATP
Trace c: Reversal of ATP inhibition by 30 JlM Diazoxide (the trace almost
superimposes on the open trace)
Trace d: Reinhibition by 300 JlM 5-hydroxydecanoate in the presence of30 JlM
diazoxide and 0.2 mM ATP (the trace almost superimposes on trace 'b')
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Glibenclaride inhibits dazoxide activated nit~TP
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Fig 5: Glibenclamide inhibits the pharmacological opening of mitoKATP by
diazoxide. Light scattering traces of mouse heart mitochondria respiring on
succinate rich IC medium (120 mM) at 30.5
The light scattering parameter p,
an index of matrix volume, is plotted against time.

°c.

Trace a: Resting mitoKATP channel in open state (control)
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM)
Trace c: Activation ofmitoKATP by diazoxide (30 J.1M) in the presence of ATP (0.2

mM) (the trace almost superimposes on the open trace)
Trace d: Inhibition of diazoxide activated mitoKATP by glibenclamide (l0 J.1M) in the
presence of ATP (the trace almost superimposes on trace 'h')
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5HD inhibits cromakaIim activated nitoKAlP
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Fig 6: 5-hydroxydecanoate (5 HD) inhibits cromakalim (CRM) activated
mitoKATP. Light scattering traces showing the activity of mitoKATP in mouse heart
mitochondria respiring on succinate supplemented IC medium (120 mM) at 30.5
°C. The light scattering parameter p, an index of matrix volume, is plotted
against time.
Trace a: Resting mitoKATP channel in open state (control)
Trace b: Inhibition of mitoKATP by ATP (0.2 mM)
Trace c: Activation ofmitoKATP by cromakalim (50 JlM) in the presence of ATP (0.2
mM) (the trace almost superimposes on control trace)
Trace d: Inhibition of cromakalim activated mitoKATP by 5HD (300 JlM) in the
presence of ATP (the trace almost superimposes on trace 'b')

35

Glibenclanide inhibits CromakaIim activated nit~1P
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Fig 7: Glibenclamide inhibits the cromakalim activated mitoKATP.Light
scattering traces showing the activity of mitoKATP in mouse heart mitochondria
respiring on succinate supplemented IC medium (120 mM) at 30.5 °C. The light
scattering parameter p, an index of matrix volume, is plotted against time.
Trace a: Resting mitoKATP channel in open state (control)
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM)
Trace c: Activation ofmitoKATP by cromakalim (50 JlM) in the presence of ATP (0.2
mM) (trace almost superimposing on trace 'a')

Trace d: Inhibition of cromakalim activated mitoKATP by glibenclamide (10 JlM) in
the presence of A TP (the trace almost superimposes on trace 'b')
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Glibenclarride inhibits PNIA activated nit~1P
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Fig 8: Glibenclainide inhibits the PMA activated mitoKATP. Light scattering
traces showing the activity of mitoKATP in mouse heart mitochondria respiring on
succinate supplemented K+ medium (120 mM) at 30.5 °C. The light scattering
parameter p, an index of matrix volume, is plotted against time.
Trace a: Resting mitoKATP channel in open state (control)
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM)
Trace c: Activation of mitoKATP by PMA (0.2 J.1M) in the presence of ATP (0.2 mM)
(trace almost superimposing on trace 'a')
Trace d: Inhibition of PMA activated mitoKATP by glibenclamide (10 J.1M) in the
presence of ATP (the trace almost superimposes on trace 'b')
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5HD inhibits PMAactivated nit~1P
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Fig 9: 5 HD inhibits PMA activated mitoKATP. Light scattering traces showing the
activity of mitoKATP in mouse heart mitochondria respiring on succinate
supplemented ~ medium (120 mM) at 30.5 °C. The light scattering parameter p,
an index of matrix volume, is plotted against time.
Trace a: Resting mitoKATP channel in open state
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM)
Trace c: Activation of mitoKATP by PMA (0.2 JlM) in the presence of ATP (0.2 nlM)
(trace seen almost superimposing trace 'a')

Trace d: Inhibition of PMA activated mitoKATP by 5 HD (300 JlM) in the presence of
ATP (the trace almost superimposes on trace 'b')
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Fig 10: Summarized data for the percentage mitoKATP activity exhibited by
isolated mouse heart mitochondria when subjected to KCO diazoxide and
blockers 5 hydroxydecanoate (5 HD) and glibenclamide. The results summarized
are for five independent experiments for each combination. Error bars represent
SDs from the average of five individual experiments.

Open: Control traces with no ATP (100% mitoKATP activity)
ATP: % mitoKATP activity in the presence of 0.2 mM ATP (0%)

DZX: % mitoKATP activity in the presence of 30 JlM diazoxide + 0.2 mM ATP
DZX+5-HD: % mitoKATP activity with 30 JlM DZX+ 300 JlM 5-HD+ 0.2 mM ATP
DZX+GLI: % mitoKATP activity with 30 JlM DZX+ 10JlM glibenclamide + 0.2 mM
ATP
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Fig 11: Summarizing the % mitoKATP activity exhibited by isolated mouse heart
mitochondria when subjected to cromakalim alone and in combination with 5
HD and glibenclamide. The results summarized are for N=5 for each
combination. Error bars represent SDs from the average of five individual
experiments.
Open: Control traces with no ATP (100% mitoKATP activity)
ATP: % mitoKATP activity in the presence of 0.2 mM ATP (0%)
CROM: % mitoKATP activity in the presence of 50 flM cromakalim + 0.2 mM ATP
CROM+5-HD: % mitoKATP activity with 50 flM cromakalim+ 300 flM 5-HD+ 0.2
mMATP
CROM+GLI: % mitoKATP activity with 50 flM cromakalim+ lOflM glibenc1amide +
0.2mMATP
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Fig 12: Summarizing the % mitoKATP activity exhibited by isolated mouse heart .
mitochondria when subjected to PMA alone and in combination with 5-HD and
glibenclamide. The results summarized are for N=5 for each combination. Error
bars represent SDs from the average of five individual experiments.
Open: Control traces with no ATP (100% mitoKATP activity)
ATP: % mitoKATP activity in the presence of 0.2 mM ATP (0%)
PMA: % mitoKATP activity in the presence of 0.2 JlM PMA + 0.2 mM ATP
PMA+5-HD: % mitoKATP activity with 0.2 JlM PMA+ 300 JlM 5-HD+ 0.2 mM ATP
PMA+GLI: % mitoKATP activity with 0.2 JlM PMA+ 10JlM glibenc1amide + 0.2 mM
ATP
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Mt~TP activity in rat heart nitochondria
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Fig 13: A typical light scattering trace showing the activity of mitoKATP in rat
heart mitochondria under the same experimental conditions i.e., respiring on
succinate supplemented K+ medium (120 mM) at 30.5 °C. The light scattering
parameter p, an index of matrix volume, is plotted against time.
Trace a: Resting mitoKATP channel in open state (controVopen)
Trace b: Inhibition ofmitoKATP by ATP (0.2 mM) (+ ATP)
Trace c: Activation of mitoKATP by Keo diazoxide (30 JlM) in the presence of ATP
Trace d: Inhibition of activated mitoKATP by 5 HD (300 JlM) in the presence of ATP
and diazoxide
Note: The results obtained with the combination of diazoxide and 5 HD were
reproducible by combining diazoxide + glibenc1amide (10 JlM), cromakalim (50 JlM)
+ 5 HD or cromakalim + glibenclamide, and also PMA (0.2 JlM) + 5 HD or PMA +
glibenc1amide. (data not shown)
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Fig 14: The following figure compares the % mitoKATP activity activity exhibited by
both rat and mouse heart mitochondria under the same experimental conditions and in
the presence of various potassium channel openers and blockers. Error bars represent
SDs from the average of five individual experiments. The rates in the absence of A TP
(open) were set as 100% and in the presence of A TP as 0%. The various openers and
blockers are analyzed in relation to these set controls.
•

•
•

Diazoxide (DZX) has caused a significant reactivation of the mitoKATP in both
rat and mouse heart mitochondria. This effect is significantly inhibited by 5HD
in both study models.
The openable effects of cromakalim (CRM) on mitoKATP are significantly
inhibited by 5HD in both rat and mouse heart mitochondria.
The activation of mitoKATP by PMA is significantly inhibited in the presence
of 5HD in both the study models.
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Fig 15: Chemical structures of K ATP channel activators
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Fig 16: Chern·Ical structures of K ATP blockers
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CHAPTER 6
DISCUSSION:
Mitochondrial ATP sensitive potassium channels (mitoKATP) are believed to be
integral in the physiology of cardioprotection and cardiac ischemia related
manifestations [46, 47, 72, 77]. The various cardioprotective drugs such as diazoxide
are thought to act through the mitoKATP and hence involved in cardioprotection, as
evidenced by the infarct size post ischemic-preconditioning and ischemia-reperfusion
injury [46, 47, 51, 75, 78, 82].
ATP-sensitive potassium channels (KATP ) are found in a variety of tissues that include
pancreatic

~-cells,

neurons of brain parenchyma, heart, skeletal and smooth muscle

cells [1]. Cardiac cells contain two divergent KATP channels, the classical one in the
sarcolemma (cellKATP) [1] and the other in the inner membrane of the mitochondria
(mitoKATP) [44, 73]. Garlid et aL observed that the mitoKATP exhibited several
properties comparable to those of the cellKATP . [45,69, 77, 90]
CellKATP are implicated in a variety of roles and are implemental in transitioning the
metabolic status of a cell into a physiological effect [21, 86, 87, 88, 89]. Kir and SUR
subunits, that are heteromultimers, constitute the cellKATP [29,31,69, 90]. Kir is
believed to assemble with SUR as a 4:4 complex and function as an octameric channel
[29,31,41,42,69,90]. The SURs are members of the ATP-binding cassette (ABC)
family [29, 31, 69, 77]. The genes that encode SURI and SUR2 are mostly
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homologous, while SUR2A (cardiac) and 2B (smooth muscle) are splice variants [29,
77, 90]. SURI is thought to regulate the pancreatic ~ channel activity, SUR2A the
cardiac channel, and SUR 2B the smooth muscle channel [29, 30, 31, 77]. Kir
channels are tetramers and have two transmembrane domains linked by a pore loop.
[29, 30, 31, 37, 77]
The subunits that configure the mitoKATP are thought to be qualitatively equivalent to
the cellKATP [77, 90]. The activity ofmitoKATP is modulated by various biochemical
and pharmacological agents, some reacting with mitoSUR (mitochondrial sulfonylurea
receptor), and others with mitoKir (mitochondrial inward rectifying potassium channel
receptor) [Fig 2] [77, 78, 90]. Garlid et al. showed that mitoKATP is a high affinity
receptor for K+ channel openers (KCOs), including cromakalim, diazoxide and PMA
(a PKCB activator), and this activation is inhibited in the presence of 5 HD and
glibenclamide. [46,47,48, 72, 75, 90]
Through my experiments I have tried to characterize the activity of mitoKATP in the
mitochondria of control mouse by testing the activity of this channel in the presence of
various specific and non-specific potassium channel openers and their blockers. It was
evident from my results that the cpannel was significantly active in the mouse heart
mitochondria. The light scattering traces initiated in the presence of various KCOs and
their inhibitors showed results that were comparable to those in the rat heart
mitochondria [Fig 13 & 14]. The various selective and non-selective activators and
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inhibitors of the channel exhibited their activity at a concentration that was identical to
that used for the rat heart mitochondria. Diazoxide, a selective KCO activated the
channel in 30 J.lM range, a concentration at which a significant channel activity was
witnessed in rat heart. This activator effect of diazoxide was inhibited by 5 HD (300
J.lM) and glibenc1amide (10 J.lM). Cromakalim, a non-selective KCO demonstrated
significant channel opening when added as a 50 J.lM final concentration. The channel
activity was inhibited by both 5 HD and glibenc1amide. PhorboI12-myristate-13
acetate (PMA), which is a PKC6 (Protein Kinase C epsilon) activator, caused a
significant activation of the mitoKATP in the 0.2 J.lM range; an effect that was inhibited
by 5-hydroxydecanoate (5 HD). Channel activity was evident considering and
comparing the rates of various light scattering traces initiated.
The mitoKATP activity, having been characterized in control mouse heart
mitochondria, would eventually be an ideal platform to explore further the structural
components of the mitoKATP . The model of transgenic mouse/genetically modified
mouse, powered with the light scattering technique and immunological tools such as
western blots and immunoflorescence techniques, would be one of the most ideal and
logistic extensions in identifying and establishing the subunit assembly of the
mitoKATP • Also, from the data analysis it seems evident that the mitoKATP activity
exhibited by control mouse heart mitochondria is similar and comparable to that
exhibited by the rat heart mitochondria considering the channel activity exhibited in
the presence of various potassium channel openers and their blockers. The data
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validates the use of the mouse as a comprehensive study model for the analysis of
mitoKATP activity in the heart mitochondria.
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APPENDIX A: Mouse heart mitochondria isolation protocol

Solutions

BufferB

Buffer A

Sucrose
HEPESpH7.2

Sucrose

250mM

HEPESpH 7.2

10mM

EGTA

5mM

BSA

5 mglmL

EGTA

250mM
10mM
5mM

[i.e. Buffer A without BSA]

Procedure

1. Anesthetize 2-3 mice with carbon dioxide (--30 sec)
2. Quickly remove heart(s) and place in a 20 mL beaker, on ice, filled with ice-cold
BufferB.
3. Using a squeezing action, manually remove as much blood as possible. Decant off
the bloody buffer. (--15 sec)
4. Add 10-15 mL of Buffer B supplemented with 1mglmL protease (Nagarse 
protease Sigma Type XXIV) and cut into very small pieces with a sharp scissor. (30
60 sec)
5. Pour the diced suspension into a 50 mL, ice-jacketed Potter-Elvegen tissue grinder
with Teflon pestle, add 30-40 mL ice-cold Buffer A and homogenize at moderate
speed (75% of max). Usually 5-6 strokes are enough for a good homogenization.
NOTE: Additional strokes will not necessarily increase protein yield, but certainly will
increase the time of isolation and thus mitochondria exposure to protease, although
Buffer A contains 0.5% BSA. (30-60 sec)
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6. Pour the homogenate into two (2) pre-cooled 50 mL centrifuge tubes and centrifuge
3 minutes x 1500g.
7. Decant the supernatant into two, clean, pre-chilled 50 mL centrifuge tubes and
centrifuge 5 minutes x 10,000g.
8. Discard the supernatants and resuspend each of the pellets in --0.5 mL of Buffer B
using a pipetor to gently "wash" the pellets into homogeneous suspension. Combine
all suspensions into one (l) 50 mL centrifuge tube, fill with Buffer B, and centrifuge 3
minutes x 2300g.
9. Carefully decant the supernatant (containing the mitochondrial fraction) into a
clean, pre-chilled 50 mL centrifuge hlbe. Discard the "fluffy" pellet that results from
this low-speed spin.
10. Centrifuge the supernatant for 5 minutes x 10,000 g.
11. Pour off (discard) the supernatant, and resuspend the pellet in --150 to 200 J!L of
Buffer B (see Step 8, above).
12. Alternatively, the centrifugation times can be cut to 3-5-3-5 min, respectively
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